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PAcute Coronary Syndrome
nhanced Plasma Levels of Oxidized Low-Density
ipoprotein Increase Circulating Nuclear Factor-
appa B Activation in Patients With Unstable Angina
uciano Cominacini, MD,* Maurizio Anselmi, MD,† Ulisse Garbin, MD,* Anna Fratta Pasini, MD,*
hiara Stranieri, BSC, PHD,* Massimiliano Fusaro, MD,† Cristina Nava, MD,*
ierfrancesco Agostoni, MD,† Dritan Keta, MD,† Pietro Zardini, MD,† Tatsuya Sawamura, MD, PHD,‡
incenzo Lo Cascio, MD*
erona, Italy; and Osaka, Japan
OBJECTIVES The purpose of this study was to investigate the effect of circulating levels of oxidized
low-density lipoprotein (ox-LDL) on nuclear factor-kappa B (NF-kB) activation in periph-
eral blood mononuclear cells (PBMC) of patients with unstable angina (UA) or stable angina
(SA) and control subjects.
BACKGROUND Nuclear factor-kB might be involved in atherosclerosis, as is suggested by the presence of
activated NF-kB in human atherosclerotic lesions.
METHODS Levels of plasma ox-LDL and circulating NF-kB in PBMC (and in separated lymphocytes
and monocytes) were measured in 27 control subjects and 29 SA and 27 UA patients. In in
vitro studies, the effect of ox-LDL and of the sera derived from a subgroup of UA patients
and control subjects on monocytic NF-kB activation was also evaluated.
RESULTS The UA and SA patients had higher levels of circulating ox-LDL and NF-kB in PBMC than
control subjects (p  0.001). The increase in circulating NF-kB was mainly due to the
activation of monocytes. In the in vitro studies, ox-LDL dose-dependently increased the
activation of NF-kB in monocytes, but not in lymphocytes derived from healthy volunteers.
This increase was related to the expression of lectin-like ox-LDL receptor-1 on monocytes.
The incubation of monocytes with the sera derived from the UA patients induced a significant
increase in NF-kB activation compared with the sera derived from the control subjects.
CONCLUSIONS The data suggest that the activation of NF-kB in monocytes of UA patients is, at least in part,
induced by circulating molecules such as ox-LDL, which has been found to be particularly
elevated in UA patients. (J Am Coll Cardiol 2005;46:799–806) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.063College of Cardiology Foundation
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there is increasing evidence that inflammation plays an
mportant role in atherogenesis and might determine plaque
ulnerability (1). Many of the genes involved in the acute
nflammatory response that are pivotal in the atherogenic
rocess are activated by the nuclear factor-kappa B (NF-kB)
2). Nuclear factor-kB resides inactive and bound to the
nhibitory protein-kappa B (I-kB) in the cytoplasm of many
ell types, including T-lymphocytes, monocytes, macro-
hages, endothelial cells, and smooth muscle cells (3,4).
umerous stimulants—including cytokines and oxidants (5)
uch as oxidized low-density lipoprotein (ox-LDL) (6)—
lter I-kB, causing nuclear translocation of NF-kB.
Nuclear factor-kB was demonstrated to be present in
uman coronary plaque and enhanced in patients with
From the *Department of Biomedical and Surgical Sciences, Section of Internal
edicine, and the †Section of Cardiology, University of Verona, Verona, Italy; and
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saka, Japan. This work was supported in part by grants from the Ministry of
niversity and Scientific Research of Italy; the Ministry of Culture, Sports, Science,
nd Technology of Japan; the ministry of Health, Labour, and Welfare of Japan; the
rganization for Pharmaceutical Safety and Research; Takeda Science Foundation;
nd DNO Medical Research Foundation.L
Manuscript received January 19, 2005; revised manuscript received March 7, 2005,
ccepted May 9, 2005.nstable angina (UA) (7,8). Recent work has shown an
ssociation between increasing circulating level of NF-kB in
eripheral blood mononuclear cells (PBMC) and UA (8).
o far, it is unclear whether NF-kB activation in the
irculation of patients with UA represents cause or effect,
ith peripheral activation of the transcription factor occur-
ing in response to a stimulus in the coronary circulation or
he coronary event itself occurring as a reaction to circulat-
ng inflammation.
Recent data indicate that circulating levels of ox-LDL are
igh in acute coronary syndromes (ACS) and, in particular,
n UA (9). The mechanisms leading to this increase are
nclear. However, it is known that plaque instability corre-
ates with the location of macrophages, T cells, and mast
ells within the plaque (1). Moreover, macrophage-rich
laques have been recently shown to contain higher con-
entration of ox-LDL than macrophage-poor plaques
10,11) and to be associated with elevated levels of ox-LDL
n plasma (10). Taken together, this evidence suggests that
lasma and plaque levels of ox-LDL may be correlated with
he vulnerability to rupture of atherosclerotic lesions.
There are many scavenger receptors that can bind ox-
DL (12). Currently, however, the majority of these recep-
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Circulating ox-LDL and NF-kB in Unstable Angina September 6, 2005:799–806ors have been shown to be mostly non-signaling molecules
nd to play a key role in foam cell formation (13). In
ontrast, ox-LDL/lectin-like ox-LDL receptor-1 (LOX-1)
nteraction has already been shown to modulate cellular
unction (14) and to induce NF-kB activation in endothelial
ells (15).
Therefore, the aim of this study was to assess the role of
lasma ox-LDL and LOX-1 on circulating NF-kB activa-
ion in patients with UA.
ETHODS
tudy population. This study was approved by our hospital
thical committees, and informed consent was obtained
rom all patients before their enrolment.
Major requirements for enrollment in all the groups were:
bsence of infectious or acute/chronic inflammatory dis-
ases, known malignancy, absence of acute/chronic renal
ailure, or hepatic failure. Three groups of patients were
tudied.
TABLE ANGINA (SA) GROUP. This group comprised patients
ith typical effort anginal pain associated with documenta-
ion of inducible ischemia during exercise stress test, defined
s ST-segment depression 1 mm on the electrocardio-
ram during bicycle ergometry or ipo/akinesia of one or
ore normocontractile segments of the cardiac wall during
tress-echo; no significant worsening of the symptoms in the
revious two months; and no anginal episodes in the week
efore enrollment.
A GROUP. This group comprised patients with at least two
pisodes of rest anginal pain or one episode lasting more
han 20 min in the previous 48 h (class IIIB unstable angina,
ccording to Braunwald’s classification) (16), preferably, but
ot necessarily, associated with electrocardiographic modi-
cations (T-wave inversion, ST-segment depression, tran-
ient ST-segment elevation) and a normal value of
-troponin on admission and during the first 24 h.
Abbreviations and Acronyms
ACS  acute coronary syndrome
CAD  coronary artery disease
HDL  high-density lipoprotein
IgG  immunoglobulin G
LOX-1  lectin-like ox-LDL receptor-1
LPDS  lipoprotein-depleted serum
mAb  monoclonal antibody
mRNA  messenger ribonucleic acid
NF-kB  nuclear factor-kappa B
ox-LDL  oxidized low-density lipoprotein
PBMC  peripheral blood mononuclear cells
PCI  percutaneous coronary intervention
RT-PCR  reverse transcriptase-polymerase chain
reaction
SA  stable angina
UA  unstable anginaFor both SA and UA patients, exclusion criteria were: revious coronary artery bypass grafting, recent (6
onths) myocardial infarction, recent (6 months) percu-
aneous coronary intervention (PCI), congestive heart fail-
re, and coronary tree free of significant coronary artery
isease (CAD) (defined as at least one stenosis with
inimal luminal diameter 70% of the arterial lumen by
isual estimate) detected at coronary angiography.
ONTROL GROUP. This group comprised patients affected
y valvular or congenital heart disease, but without a clinical
istory of CAD, who underwent coronary angiography for
pre-surgical evaluation. The only exclusion criterion was
etection of significant CAD during coronary angiography.
The following data were obtained from all patients: age,
ender, presence of CAD risk factors (hypertension, ciga-
ette smoking, diabetes mellitus, hypercholesterolemia,
amily history of CAD), use of medications, previous
yocardial infarction, and previous revascularization (PCI
r coronary artery bypass grafting).
lood samples. Venous blood samples were obtained from
A and control patients the morning after the day of
dmission. In UA patients, samples were drawn within 24 h
rom the index event (the last episode of anginal pain or
dmission if angina occurred previously). Blood was col-
ected from each patient and drawn into pyrogen-free blood
ollection tubes without additives. Multiple aliquots of
erum were placed into sterile 5-ml screw-capped polypro-
ylene vials and stored at 80°C in plastic bags. Samples
ere kept frozen for no longer than 30 days, with an average of
1 days. For thawing, serum tubes were placed overnight in a
efrigerator at 2°C to 8°C. The presence of flocculent material
as removed by aseptic filtration through a sterile 0.45-m
lter. The samples were frozen and thawed only once.
Plasma levels of total cholesterol, high-density lipopro-
ein (HDL) cholesterol, LDL cholesterol, triglycerides,
lucose, white blood cell count with differential count, and
igh-sensitivity C-reactive protein were measured with
tandard techniques used in the Central Laboratory of
erona University Hospital. Levels of plasma ox-LDL and
irculating NF-kB in PBMC and in separated lymphocytes
nd monocytes and of LOX-1 messenger ribonucleic acid
mRNA) and protein expression were measured by investi-
ators blinded to the clinical and angiographic characteris-
ics of the patients.
BMC and monocyte isolation. Peripheral blood mono-
uclear cells were separated, as previously described (17), in
ll subjects enrolled in the study. Isolation of monocytes and
ymphocytes was performed in 10 subjects of each group.
onocytes and lymphocytes were isolated from PBMC by
egative or positive selection with a cocktail of hapten-
onjugated antibodies and magnetic microbeads coupled to
n anti-hapten monoclonal antibody (No touch monocyte
solation kit; Miltenyi Biotec, Auburn, California) and
epletion on a column in a magnetic field (VarioMACS,
iltenyi Biotec). Monocyte and lymphocyte purity was
97%, as assessed by flow cytometry (data not shown).
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September 6, 2005:799–806 Circulating ox-LDL and NF-kB in Unstable AnginaEndotoxin contamination of cell cultures, involving the
se of ox-LDL and lipoprotein-depleted serum (LPDS),
as routinely excluded with the chromogenic limulus ame-
ocyte lysate assay (Sigma, St. Louis, Missouri). Further-
ore, all cell cultures were set up in the presence of 10
g/ml polymixin B to neutralize any potential lipopolysac-
haride contamination.
F-kB measurement. Nuclear factor-kB activation was
easured by two methods: 1) by a sensitive multi-well
olorimetric assay for active NF-kB (TRANS-AM; Active
otif, Rixensart, Belgium), as previously described (18);
nd 2) by flow cytometry, to differentiate NF-kB activation
n lymphocytes and monocytes. As a reference, recombinant
65 (Active Motif) was used.
Flow cytometric analysis was performed according to a
reviously published procedure (19). Whole blood cells were
abeled with phycoerythrin-conjugated anti-CD14 mono-
lonal antibodies and peridinin chlorophyll protein-
onjugated anti-CD3 monoclonal antibodies. The cells were
hen labeled with mouse anti–NF-kB (nuclear-localized signal)
ntibodies (IgG3; Boehringer Mannheim, Mannheim, Ger-
any), recognizing an epitope overlapping the nuclear location
ignal of NF-k-p65, and therefore, the activated form of
F-kB. The cells were then labeled with fluorescein
sothiocyanate-conjugated rat anti-mouse IgG3 monoclonal
ntibodies (Pharmingen, San Diego, California). Immunoflu-
rescence staining was analyzed with a FACScan flow cytom-
ter, equipped with CellQuest software (Becton-Dickinson
iosciences, San Jose, California).
xidized LDL assay. The ox-LDL were measured with
he enzyme-linked immunosorbent assay Mercodia Oxi-
ized LDL ELISA kit, in which the wells of the microtiter
lates are coated with the capture monoclonal antibody
mAb)-4E6 (9) (Mercodia AB, Uppsala, Sweden), follow-
ng the method described by Holvoet et al. (20). As a
tandard solution, Cu2-modified LDL, ranging from 50 to
00 ng/ml, was used.
DL isolation and oxidation. Whole blood from healthy
olunteers, containing ethylenediamine tetraacetic acid
EDTA) (1 mg/ml), was processed for LDL separation as
reviously described (21). Cu2-modified LDL was pre-
ared as previously reported (15).
OX-1 mRNA and protein expression in separated
ymphocytes and monocytes. Separated monocytes and
ymphocytes were from pools derived from control subjects
nd SA and UA patients. Total RNA was extracted from
ells by the RNAse mini kit (Qiagen, Venlo, the Nether-
ands). Reverse-transcriptase polymerase chain reaction
RT-PCR) was performed with the TwoStep RT-PCR kit
Invitrogen, Carlsbad, California). For each reaction, 1 g
f total RNA served as a template. For amplification, a
rimer pair specific for human LOX-1 (sense primer, 5=-
TACTCTCCATGGTGGTGCC-3=; antisense primer,
nd 5=-AGCTTCTTCT DCTTGTTGCC-3=) was used;
eta-ACTIN (5=-ATCTGGCACCACACCTTCTAC-3=
nd 5=-GAGGCGTACAGGGATAGCAC-3=) was used as an internal standard in the PCR mixture. A 199-bp human
OX-1 complementary DNA (cDNA) fragment and a
82-bp human beta-ACTIN cDNA fragment were enzy-
atically amplified by 30 and 22 repeated cycles, respec-
ively. An aliquot of each reaction mixture was then sub-
ected to electrophoresis on 1.5% Tris-acetate EDTA
garose gel containing ethidium bromide. The intensity of
he bands was measured with an image analysis scanning
ystem (Alpha Imager 2000; Packard Instruments, Meri-
en, Connecticut).
The LOX-1 protein expression was analyzed in mono-
ytes and lymphocytes by flow cytometry, as described
reviously, using a specific anti-LOX-1 mAb (22).
xidized LDL-dependent activation of NF-kB in mono-
ytes. Purified monocytes (3  105/ml, 200 l/well) from
ealthy donors were cultured in 96-well trays (Costar, Cam-
ridge, Massachusetts) in RPMI 1640 with L-glutamine
GIBCO; Invitrogen) for 20 h at 37°C, with increasing
mounts of ox-LDL (from 10- to 40-g/ml medium as
easured by the previously specified enzyme-linked immu-
osorbent assay).
In some experiments, blocking anti-LOX-1 mAb (20
g/ml) or control mouse immunoglobulin G (IgG) (50
g/ml) was also added to cell culture. Nuclear factor-kB was
easured in cellular extract of monocytes as previously
ndicated.
lasma-dependent activation of NF-kB in monocytes. Pu-
ified monocytes (3  105/ml, 200 l/well) from healthy
olunteers were cultured in 96-well trays (Costar) in RPMI
640 with L-glutamine (GIBCO) for 20 h at 37°C with
0% serum from 10 UA patients with the highest ox-LDL
evels or control subjects with the lowest ox-LDL values.
or processing of serum, 80 l of serum from each patient
r control subject was added to the monocyte culture
mmediately after thawing, at the start of the culture period.
In some experiments, anti-LOX-1 mAb (20 g/ml) or
ontrol human IgG (50 g/ml) was also added to the cell
ulture.
As a further control, monocytes were also incubated with
he corresponding LPDS in which all the lipoproteins were
aken away by ultracentrifugation at a density 1.21 g/ml,
ollowing the previously indicated method (21).
tatistical analysis. Continuous data are expressed as mean
SD values, if normally distributed. Median (interquartile
ange) was used for variables not normally distributed.
ormal distribution of the data was determined with the
hapiro-Wilk test. Differences between continuous data
ere analyzed by the two-tailed unpaired Student t test.
tatistical comparison among three groups was performed
y one- or two-way analysis of variance and post-hoc
ultiple comparison with Student-Newmann-Keuls’ test, if
parametric distribution was assessed. If the data were not
arametric, analysis of variance on ranks and post-hoc
unn’s tests were used. Relationship between variables wasssessed by linear regression. A probability value 0.05 was
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Circulating ox-LDL and NF-kB in Unstable Angina September 6, 2005:799–806onsidered statistically significant. All data were analyzed
ith SPSS 11.01 for Macintosh (SPSS, Chicago, Illinois).
ESULTS
aseline characteristics of the patients. During a period
f 14 months, 102 patients were enrolled in the study; of
hese patients, only 82 (27 control subjects, 29 with SA, and
7 with UA) fully satisfied the enrollment criteria. Baseline
linical characteristics of the patients are listed in Table 1. In
he control group, there were more women and fewer
atients with hypercholesterolemia than in the SA and UA
roups (p  0.05); in the SA group, there were more
atients with a history of ACS or PCI than in the UA group
p  0.01) and more patients taking aspirin than in the
ontrol group (p  0.05).
aboratory data. Data on total, LDL, and HDL choles-
erol, triglycerides, glucose plasma levels, white blood cell
ount, and C-reactive protein are shown in Table 2.
here were no significant differences in total, LDL, or
DL cholesterol, triglycerides, or glucose levels; the total
hite blood cell counts and C-reactive protein levels were
igher in UA patients than in SA or control patients (p
0.001).
irculating ox-LDL and NF-kB. Figures 1A and 1B
how the levels of ox-LDL (expressed in g/ml) and
Table 1. Baseline Clinical Characteristics of th
C (n  27)
Age (yrs) 66  11
Women 9 (33%)*
Risk factors
Family history 0 (37%)
Smoke 5 (18%)
Hypercholesterolemia 11 (41%)*
Hypertension 3 (48%)
Diabetes 2 (7%)
Current therapy
ACE inhibitors 17 (63%)
Statins 3 (11%)
Aspirin 8 (30%)
Clinical history
Previous ACS —
Previous PCI —
Data are expressed as numbers and percent. *C versus SA a
ACE  angiotensin-converting enzyme; ACS  acute
coronary intervention; SA  stable angina; UA  unstable
Table 2. Laboratory Data of the Three Group
C (n  27)
Total cholesterol (mg/dl) 206.1  25.9
LDL cholesterol (mg/dl) 133.0  26.4
HDL cholesterol (mg/dl) 49.9  9.42
Triglycerides (mg/dl) 135.5  69.4
Glucose (mg/dl) 106.3  25.6
White blood cells (109/l) 6.75  1.57
CRP (mg/dl) 0.43 (0.08–0.83)
*UA versus SA and C.
CRP  C-reactive protein; HDL  high-density lipoprotein;
Table 1.ctivated NF-kB (expressed in ng/g cell protein) in the
hree groups of patients. The ox-LDL level differed signif-
cantly among groups. In particular, post-hoc tests re-
ealed a significant difference between UA and SA
atients and control subjects and between SA patients
nd control subjects (p from 0.001 to 0.01). Also,
F-kB in PBMC (Fig. 1B) results were significantly
ifferent in the three groups of patients. The UA and SA
atients had higher levels of circulating NF-kB than
ontrol patients (p  0.001). Furthermore, a statistically
ignificant difference was observed between SA and UA
atients (p  0.01).
In the whole population, a statistically significant corre-
ation was detected between ox-LDL in plasma and NF-kB
n PBMC (r  0.68, p  0.001) (Fig. 2).
ercentage of CD3 T cells and CD14 monocytes
xhibiting NF-kB activation. By flow cytometry, there
as only a slight increase in the percentage of CD3 T cells
xhibiting NF-kB activation in UA and SA patients and in
ontrol subjects, and there were no significant differences
mong the three groups (Table 3). In contrast, the percent-
ge of CD14 monocytes exhibiting NF-kB activation was
igh, and there were significant differences among the three
roups (Table 3). In particular, UA and SA patients had a
igher percentage of NF-kB activation in CD14 mono-
ree Groups of Patients
(n  29) UA (n  27) p Value
61  9 61  9 NS
3 (10%) 3 (11%) 0.05
9 (66%) 10 (38%) NS
8 (28%) 12 (46%) NS
3 (79%) 18 (69%) 0.05
3 (79%) 16 (61%) NS
4 (14%) 4 (15%) NS
7 (59%) 9 (35%) NS
7 (24%) 3 (11%) NS
2 (76%)† 13 (50%) 0.05
9 (65%)‡ 8 (31%) 0.01
3 (45%)‡ 2 (8%) 0.01
; †SA versus C; ‡SA versus UA.
ary syndrome; C  control subjects; PCI  percutaneous
.
atients
A (n  29) UA (n  26) p Value
06.4  23.4 215.0  27.1 NS
36.5  4.5 139.9  27.4 NS
46.8  10.9 44.4  8.50 NS
39.9  49.6 155.0  66.2 NS
97.3  18.0 100.8  16.2 NS
6.51  1.81 9.07  1.63* 0.001
1 (0.08–1.21) 0.98 (0.25–2.01)* 0.001e Th
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September 6, 2005:799–806 Circulating ox-LDL and NF-kB in Unstable Anginaytes than control patients (p  0.001) (Table 3). A
tatistically significant difference was also observed between
A and UA patients (p  0.01) (Table 3).
igure 1. (A) Concentrations of plasma oxidized low-density lipoprotein
Ox-LDL) in unstable angina (UA) and stable angina (SA) patients and in
ontrol subjects. *p 0.001 vs. control subjects; †p 0.01 vs. SA patients.
B) Concentrations of circulating nuclear factor-kB (NF-kB) in UA and
A patients and in control subjects. The NF-kB was extracted from
eripheral blood mononuclear cells derived from UA and SA patients and
ontrol subjects. *p 0.001 vs. control subjects; †p 0.01 vs. SA patients.
igure 2. Correlation between the concentrations of plasma oxidized
ow-density lipoprotein (Ox-LDL) and the circulating levels of nuclear
actor-kB (NF-kB) in all subjects considered in the study.
U
cF-kB activation in separated lymphocytes and mono-
ytes. The results on NF-kB activation in CD14 mono-
ytes were confirmed by directly measuring NF-kB activa-
ion in separated monocytes and lymphocytes derived from
subgroup of UA, SA, and control subjects (Fig. 3). On
verage, activated NF-kB levels (expressed in ng/g cell
rotein) were higher in monocytes than in lymphocytes in
A, SA, and control subjects (p  0.001). There were no
ifferences in NF-kB levels of lymphocytes among the three
roups of subjects; conversely, monocytes of UA and SA
atients had higher levels of activated NF-kB than control
atients (p  0.001). A statistically significant difference
as also observed between SA and UA patients (p  0.01).
OX-1 mRNA and protein expression in monocytes and
ymphocytes. To examine whether LOX-1 was expressed
n lymphocytes and monocytes, we measured the level of
OX-1 mRNA and protein. Both mRNA and peptide
ere present in monocytes but not in lymphocytes (Figs.
A and 4B).
xidized LDL-dependent activation of NF-kB in mono-
ytes and lymphocytes. Different amounts of Cu2 ox-
DL (from 10 to 40 g/ml, as measured in the previously
pecified assay), incubated overnight with monocytes de-
ived from healthy volunteers, dose-dependently increased
F-kB activation (Fig. 5) (p  0.001). Oxidized LDL had
able 3. Percentage of Cells Exhibiting NF-kB Activation in
atients With Unstable Angina (UA), Stable Angina (SA), and
ontrol Subjects
CD3 CD14
A patients 4.12  1.83 76.43  8.92*†‡
A patients 3.41  1.69 44.21  8.21*†
ontrol subjects 4.10  2.51 7.21  4.13
p  0.001 versus CD3; †p  0.001 versus control subjects; ‡p  0.01 versus SA
atients.
NF-kB  nuclear factor-kappa B; other abbreviations as in Table 1.
igure 3. Concentrations of circulating nuclear factor-kB (NF-kB) in
eparated monocytes and lymphocytes derived from unstable angina (UA)
nd stable angina (SA) patients and control subjects. The NF-kB was
xtracted from the separated monocytes and lymphocytes of a subgroup of
A, SA, and control subjects. *p  0.001 vs. lymphocytes; †p  0.001 vs.
ontrol subjects; ‡p  0.01 vs. SA patients.
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Circulating ox-LDL and NF-kB in Unstable Angina September 6, 2005:799–806o effect in lymphocytes (Fig. 5). In some experiments,
nti-LOX-1 mAb (20 g/ml) or control mouse IgG (50
g/ml) was also added to the cell culture. The presence of
he blocking antibody significantly reduced the ox-LDL–
ependent activation of NF-kB in monocytes (Fig. 5) (p 
.001).
lasma-dependent activation of NF-kB in monocytes.
onocytes from healthy volunteers were evaluated for
F-kB activation after they were cultured for 20 h in a
edium supplemented with either 40% serum from 10 UA
atients with the highest ox-LDL plasma concentrations
range from 41 to 62 g/ml) or 40% serum from 10 control
ubjects with the lowest ox-LDL levels (range from 4 to 7
igure 4. (A) Basal lectin-like oxidized low-density lipoprotein receptor-1
LOX-1) messenger ribonucleic acid (mRNA) expression in pools of
eparated lymphocytes (1 to 3) and monocytes (4 to 6), derived from
ontrol subjects (1 and 4) and stable (2 and 5) and unstable (3 and 6)
ngina patients. The LOX-1 mRNA was analyzed by reverse-transcriptase
olymerase chain reaction. The LOX-1 mRNA levels were normalized to
he levels of beta-actin mRNA. Data illustrated on the bar graph represent
he mean SD of six different experiments. *p 0.001 vs. lymphocytes (1
o 3). (B) The LOX-1 protein expression in pools of separated lymphocytes
1 to 3) and monocytes (4 to 6) derived from control subjects (1 and 4) and
table (2 and 5) and unstable (3 and 6) angina patients. Lymphocytes and
onocytes were separated as described in the Methods section. The
OX-1 protein expression was analyzed by flow cytometry with a specific
nti-LOX-1 monoclonal antibody. Results are expressed as mean fluores-
ence intensity (MFI) and are means  SD of experiments performed in
riplicate on six separate occasions. *p  0.001 vs. lymphocytes (1 to 3).g/ml). The incubation of monocytes with the sera derived
v
arom the UA patients with the highest values of ox-LDL
nduced a significant increase in NF-kB activation com-
ared with the sera derived from the control subjects with
he lowest values (Fig. 6) (p  0.001).
The NF-kB activation was partially blocked by anti-
OX-1 mAb (Fig. 6) (p  0.001). The incubation of
onocytes with the LPDS of UA patients still induced a
igure 5. Oxidized low-density lipoprotein (Ox-LDL)-dependent activa-
ion of nuclear factor-kB (NF-kB) in monocytes and lymphocytes. The
urified monocytes and lymphocytes (3  105/ml, 200 l/well) were
ultured in 96-well trays for 20 h at 37°C with increasing amounts of
x-LDL in the presence of control mouse immunoglobulin G (IgG) (50
g/ml) or anti-LOX-1 monoclonal antibody (mAb) (20 g/ml). The
F-kB was measured in cellular extract as described in the Methods
ection. Results are means  SD of experiments performed in triplicate on
ix separate occasions. *p  0.001 vs. control value (ox-LDL  0 mg/ml);
p  0.001 vs. anti-LOX-1 mAb and lymphocytes. White bars 
x-LDL  monocytes  IgG; black bars  Ox-LDL  monocytes 
nti-LOX-1 mAb; ruled bars  Ox-LDL  lymphocytes  IgG.
igure 6. Plasma-dependent activation of nuclear factor-kB (NF-kB) in
onocytes. Monocytes from healthy volunteers were evaluated for NF-kB
ctivation after they were cultured for 20 h in medium supplemented with
ither 40% serum from 10 unstable angina (UA) patients with the highest
xidized low-density lipoprotein (ox-LDL) plasma concentrations (range
rom 41 to 62 g/ml) or 40% serum from 10 control subjects with the
owest ox-LDL levels (range from 4 to 7 g/ml). Monocytes were also
ncubated with the corresponding lipoprotein-depleted serum (LPDS). In
ome experiments, anti-lectin–like ox-LDL receptor-1 (LOX-1) mono-
lonal antibody (mAb) (20g/ml) or control mouse immunoglobulin G (50
g/ml) was also added to the cell culture. Results are means  SD of
xperiments performed in triplicate on six separate occasions. *p  0.001
s. serum from control subjects (C); †p  0.001 vs. serum UA 
nti-LOX-1 mAb; ‡p  0.001 vs. LPDS UA; §p  0.01 vs. LPDS C.
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he control subjects (Fig. 6). The increase, however, was
uch lower than that determined by sera in toto (p 
.001) and was not inhibited by anti-LOX-1 mAb (Fig. 6).
ISCUSSION
his study shows that circulating levels of ox-LDL and
F-kB were significantly higher in patients with UA than in
A or control patients. A difference in ox-LDL and activated
F-kB between UA and SA patients was also found.
Several studies have investigated the correlation between
linical manifestations of CAD and circulating levels of
x-LDL. The results of these studies are quite variable,
iven the heterogeneity of the populations studied and of
ntibodies used that detect different oxidation-specific
pitopes of ox-LDL (9,11,23). In our study, circulating
x-LDL concentrations were measured using the 4E6
ntibody that is directed against an epitope generated by the
ubstitution of lysine residues of apoprotein B 100 with
ldehydes (9). Holvoet et al. (9) found elevated ox-LDL
evels in patients with ACS using the 4E6 antibody, but
ailed to separate UA and SA patients. These contradictory
esults might be related to patient selection. In fact, in the
tudy by Holvoet et al. (9), troponin was not measured, and
t was not clearly specified whether their UA patients were
nly in class III or also in classes II or I, according to
raunwald’s classification (16).
In this study, we also showed that circulating NF-kB was
ore elevated in patients with UA than in patients with SA
r in control subjects without severe CAD. Our results also
how that NF-kB was significantly higher in SA patients
han in control subjects. Although for UA patients our
esults are in agreement with previous findings (8), this is
he first demonstration that circulating activated NF-kB is
lso higher in SA patients than in control subjects, indicat-
ng a progressive increase of activated NF-kB from control
ubjects without severe CAD to UA patients. At variance
ith our results, Ritchie (8) did not find any difference in
irculating NF-kB between SA patients and control sub-
ects. A likely explanation of this discrepancy might be the
act that Ritchie (8) measured NF-kB by electrophoretic
obility shift assay with subsequent densitometric semi-
uantitative evaluation of the electrophoretic bands,
hereas in this study, circulating NF-kB was evaluated with
sensitive multi-well colorimetric assay that was reported to
e at least 10 times more sensitive than electrophoretic
obility shift assay (18).
We then evaluated which cells in PBMC specifically
ontributed to the increase in circulating NF-kB activation.
t was found that the increase in circulating NF-kB activa-
ion was mainly due to the activation of monocytes. A
umber of circulating agents, including cytokines and oxi-
ants (5), or a locally produced substance at the site of
laque rupture might be responsible. In this context, for in aitro experiments, we found that ox-LDL dose-dependently
ncreased the activation of NF-kB in monocytes derived
rom healthy volunteers. In contrast, ox-LDL had no effect
n lymphocytes. These results agree with previous data
howing a deregulation of monocytic NF-kB by ox-LDL
6). The increase in monocytic NF-kB activation induced by
x-LDL was related to the expression of LOX-1 on the
onocytes, but not on lymphocytes, and was dependent on
he binding of ox-LDL to this receptor, because blocking
nti-LOX-1 mAb significantly reduced NF-kB activation.
he finding that ox-LDL did not activate NF-kB in
ymphocytes might, therefore, depend on the fact that, as
reviously shown (24), LOX-1 mRNA and protein were
ot expressed in these cells.
Finally, it has to be mentioned that the amounts of
x-LDL that increased monocytic NF-kB activation in
hese in vitro experiments ranged between 20 and 40 g/ml
edium, as measured with the same enzyme-linked immu-
osorbent assay used for plasma samples. Thus, they were in
he same order of concentration found in the plasma of UA
atients.
From these results we then evaluated the effect of sera
erived from UA patients and control subjects on NF-kB
ctivation in monocytes derived from healthy volunteers.
he results show that the sera of UA patients increased
F-kB activation at a much higher extent than those of
ontrol subjects. Because a number of circulating agents
ould potentially increase monocytic NF-kB activation, the
PDS of UA patients were then used to evaluate the
agnitude of lipoprotein effect on NF-kB activation. In
hese conditions (i.e., in absence of lipoproteins and, there-
ore, of ox-LDL), the increase in monocytic NF-kB acti-
ation was about 70% lower than that obtained with the
omplete sera. Furthermore, the fact that the contemporary
ncubation of plasma from UA patients with blocking
nti-LOX-1 mAb decreased the NF-kB activation on the
ame order of magnitude demonstrates that ox-LDL greatly
ontributes to the activation of NF-kB in monocytes of UA
atients.
Taken together, these results show that the activation of
F-kB in monocytes of UA patients might be related to the
inding of ox-LDL to LOX-1. These conclusions are in
ine with the findings that ox-LDL/LOX-1 interaction has
lready been shown to modulate cellular function (14) and
o induce NF-kB activation in endothelial cells (15).
In conclusion, the data of this study suggest that mono-
ytic activation of NF-kB in UA patients is not a primary
vent, but rather, induced, at least partially, by circulating
olecules such as ox-LDL, which have been found to be
articularly elevated in UA patients. The activation of
F-kB in these cells might participate in up-regulating the
xpression of some genes such as interleukin-8,
nterleukin-1, and tissue factor, proposed to be involved in
therogenesis (5).
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